One loan. Three bridges.

first_imgFirst and foremost, the Bridging the Gap Loan works to connect children waiting to be adopted with adoptive parents because the astronomical costs of adoption can be a major deterrent for families who would otherwise love to adopt a waiting child.This loan will serve as an important tool for adoptive families by covering the expenses associated with adoption and leading them to a credit union where they can get financial help. I fully expect many families to enter their local credit union to open an adoption loan, but then see there may be other, cheaper options such as a home equity loan.What makes this bridge unique and innovative? Other adoption loan products are existing loans (such as a home equity, car refinance, HELOC, or personal loan) with a different title. While I think that’s a good strategy to get people into the door for help, I’m proposing a new loan product for those who are well qualified, but don’t have lines of equity to pull from. The Bridging the Gap, pro-family adoption loan that I am proposing is a multi-dimensional product that acts as three bridges over three gaps all at once: 9SHARESShareShareSharePrintMailGooglePinterestDiggRedditStumbleuponDeliciousBufferTumblrcenter_img continue reading »last_img read more

Medicinal cannabis oil arrives in NZ

first_imgRadio NZ News 8 December 2017Family First Comment: Not smoked or grown in back yard like the Green Party wants. But here’s the key bit:“Trials are underway to test Tilray products’ effectiveness for treating childhood epilepsy, post-traumatic stress disorder and nausea and vomiting in chemotherapy patients.”So it’s STILL being tested for efficacy and safety. The arrival of a new, cheaper medicinal cannabis product in New Zealand is good news for patients but will still be prohibitively expensive for many, advocates say.The cannabis oil, produced by Canadian company Tilray, was first granted an export licence to New Zealand in February, but until now has only been shipped to Middlemore Hospital in Auckland.However, the first shipment that will be made available for GPs to prescribe has now arrived in the country.It contains cannabidiol (CBD) – a cannabinoid that has been shown to have therapeutic properties, but is considered a class B drug under New Zealand law so cannot be advertised or promoted by the company.Medical Cannabis Awareness New Zealand coordinator Shane Le Brun said the product had arrived “in the last week or so”.“It is now available for GPs to prescribe… [but] as an unregistered medicine they can’t make therapeutic claims and as a controlled drug they can’t advertise … so it’s kind of snuck in under the radar.”Since September, doctors have been able to prescribe CBD products without needing approval from the Health Minister.READ MORE: read more